Differential risk of castration resistance after initial radical prostatectomy or radiotherapy for prostate cancer

Hirofumi Obata, masaki shiota, Naoko Akitake, ario takeuchi, Eiji Kashiwagi, Takashi Dejima, Keijiro Kiyoshima, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto

研究成果: ジャーナルへの寄稿記事

抄録

Background/Aim: Salvage androgen-deprivation therapy (ADT) is standard treatment for recurrent prostate cancer after curative therapy. However, the prognostic impact of different treatment modalities on the time to castration resistance remains unclear. In this study, we investigated the prognosis of men treated with salvage ADT after initial radical prostatectomy or radiotherapy for prostate cancer. Patients and Methods: Between 2000 and 2013, 149 Japanese men with recurrent prostate cancer who were initially treated with radical prostatectomy (n=95) or radiotherapy (n=54) and were subsequently treated with salvage ADT after disease recurrence were enrolled in this study. The prognostic significance of the curative treatment modality and clinicopathological findings were analyzed. Results: During a median follow-up period of 4.7 years after recurrence, castration-resistant progression was observed in 22 men. The 5-year progression-free survival, metastasis-free survival, cause-specific survival, and overall survival rates for all patients were 86.3%, 81.4%, 95.7%, and 94.5%, respectively. Multivariate analysis identified the biopsy Gleason score at initial diagnosis and the initial curative treatment modality as significant predictors of castration resistance. Conclusion: This study showed that low biopsy Gleason score (≤7) at diagnosis and radical prostatectomy as the curative treatment may be favorable prognostic factors for treatment with salvage ADT.

元の言語英語
ページ(範囲)5631-5637
ページ数7
ジャーナルAnticancer research
37
発行部数10
DOI
出版物ステータス出版済み - 10 1 2017

Fingerprint

Castration
Prostatectomy
Prostatic Neoplasms
Radiotherapy
Androgens
Therapeutics
Neoplasm Grading
Biopsy
Recurrence
Salvage Therapy
Survival
Disease-Free Survival
Multivariate Analysis
Survival Rate
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Differential risk of castration resistance after initial radical prostatectomy or radiotherapy for prostate cancer. / Obata, Hirofumi; shiota, masaki; Akitake, Naoko; takeuchi, ario; Kashiwagi, Eiji; Dejima, Takashi; Kiyoshima, Keijiro; Inokuchi, Junichi; Tatsugami, Katsunori; Eto, Masatoshi.

:: Anticancer research, 巻 37, 番号 10, 01.10.2017, p. 5631-5637.

研究成果: ジャーナルへの寄稿記事

@article{ed6054c603ff4740bf72080ca4297c96,
title = "Differential risk of castration resistance after initial radical prostatectomy or radiotherapy for prostate cancer",
abstract = "Background/Aim: Salvage androgen-deprivation therapy (ADT) is standard treatment for recurrent prostate cancer after curative therapy. However, the prognostic impact of different treatment modalities on the time to castration resistance remains unclear. In this study, we investigated the prognosis of men treated with salvage ADT after initial radical prostatectomy or radiotherapy for prostate cancer. Patients and Methods: Between 2000 and 2013, 149 Japanese men with recurrent prostate cancer who were initially treated with radical prostatectomy (n=95) or radiotherapy (n=54) and were subsequently treated with salvage ADT after disease recurrence were enrolled in this study. The prognostic significance of the curative treatment modality and clinicopathological findings were analyzed. Results: During a median follow-up period of 4.7 years after recurrence, castration-resistant progression was observed in 22 men. The 5-year progression-free survival, metastasis-free survival, cause-specific survival, and overall survival rates for all patients were 86.3{\%}, 81.4{\%}, 95.7{\%}, and 94.5{\%}, respectively. Multivariate analysis identified the biopsy Gleason score at initial diagnosis and the initial curative treatment modality as significant predictors of castration resistance. Conclusion: This study showed that low biopsy Gleason score (≤7) at diagnosis and radical prostatectomy as the curative treatment may be favorable prognostic factors for treatment with salvage ADT.",
author = "Hirofumi Obata and masaki shiota and Naoko Akitake and ario takeuchi and Eiji Kashiwagi and Takashi Dejima and Keijiro Kiyoshima and Junichi Inokuchi and Katsunori Tatsugami and Masatoshi Eto",
year = "2017",
month = "10",
day = "1",
doi = "10.21873/anticanres.11998",
language = "English",
volume = "37",
pages = "5631--5637",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Differential risk of castration resistance after initial radical prostatectomy or radiotherapy for prostate cancer

AU - Obata, Hirofumi

AU - shiota, masaki

AU - Akitake, Naoko

AU - takeuchi, ario

AU - Kashiwagi, Eiji

AU - Dejima, Takashi

AU - Kiyoshima, Keijiro

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Eto, Masatoshi

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background/Aim: Salvage androgen-deprivation therapy (ADT) is standard treatment for recurrent prostate cancer after curative therapy. However, the prognostic impact of different treatment modalities on the time to castration resistance remains unclear. In this study, we investigated the prognosis of men treated with salvage ADT after initial radical prostatectomy or radiotherapy for prostate cancer. Patients and Methods: Between 2000 and 2013, 149 Japanese men with recurrent prostate cancer who were initially treated with radical prostatectomy (n=95) or radiotherapy (n=54) and were subsequently treated with salvage ADT after disease recurrence were enrolled in this study. The prognostic significance of the curative treatment modality and clinicopathological findings were analyzed. Results: During a median follow-up period of 4.7 years after recurrence, castration-resistant progression was observed in 22 men. The 5-year progression-free survival, metastasis-free survival, cause-specific survival, and overall survival rates for all patients were 86.3%, 81.4%, 95.7%, and 94.5%, respectively. Multivariate analysis identified the biopsy Gleason score at initial diagnosis and the initial curative treatment modality as significant predictors of castration resistance. Conclusion: This study showed that low biopsy Gleason score (≤7) at diagnosis and radical prostatectomy as the curative treatment may be favorable prognostic factors for treatment with salvage ADT.

AB - Background/Aim: Salvage androgen-deprivation therapy (ADT) is standard treatment for recurrent prostate cancer after curative therapy. However, the prognostic impact of different treatment modalities on the time to castration resistance remains unclear. In this study, we investigated the prognosis of men treated with salvage ADT after initial radical prostatectomy or radiotherapy for prostate cancer. Patients and Methods: Between 2000 and 2013, 149 Japanese men with recurrent prostate cancer who were initially treated with radical prostatectomy (n=95) or radiotherapy (n=54) and were subsequently treated with salvage ADT after disease recurrence were enrolled in this study. The prognostic significance of the curative treatment modality and clinicopathological findings were analyzed. Results: During a median follow-up period of 4.7 years after recurrence, castration-resistant progression was observed in 22 men. The 5-year progression-free survival, metastasis-free survival, cause-specific survival, and overall survival rates for all patients were 86.3%, 81.4%, 95.7%, and 94.5%, respectively. Multivariate analysis identified the biopsy Gleason score at initial diagnosis and the initial curative treatment modality as significant predictors of castration resistance. Conclusion: This study showed that low biopsy Gleason score (≤7) at diagnosis and radical prostatectomy as the curative treatment may be favorable prognostic factors for treatment with salvage ADT.

UR - http://www.scopus.com/inward/record.url?scp=85031098108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031098108&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11998

DO - 10.21873/anticanres.11998

M3 - Article

VL - 37

SP - 5631

EP - 5637

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -